Sugi Predict

Sugi Predict / Compounds / SCHEMBL2523178

SCHEMBL2523178

SCHEMBL2523178

N#C[C@]1(CO)O[C@@H](n2cnc3c(N)nc(F)nc32)C[C@@H]1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHCY P23526 5/20 0.52
▸ LMNA P02545 2/20 0.49
▸ NT5E P21589 2/20 0.49
▸ HIF1A Q16665 1/20 0.49
▸ PNP P00491 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ PDE3A Q14432 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ ADORA3 P0DMS8 3/20 0.41
▸ ADORA2A P29274 2/20 0.41
▸ CA5A P35218 1/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.38
▸ HSP90B1 P14625 1/20 0.38
▸ DNMT1 P26358 1/20 0.38
▸ DNMT3B Q9UBC3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2523180 1.00 AHCY (0.52) AHCYLMNANT5EHIF1APNP
SCHEMBL26286412 1.00 AHCY (0.52) AHCYLMNANT5EHIF1APNP
SCHEMBL21614183 1.00 AHCY (0.52) AHCYLMNANT5EHIF1APNP
SCHEMBL30560918 1.00 AHCY (0.52) AHCYLMNANT5EHIF1APNP
Islatravir SCHEMBL28572697 0.92 AHCY (0.50) AHCYLMNANT5EHIF1APNP
Islatravir SCHEMBL22869185 0.91 AHCY (0.51) AHCYLMNANT5EHIF1APNP
Islatravir SCHEMBL19821217 0.91 AHCY (0.51) AHCYLMNANT5EHIF1APNP
Islatravir SCHEMBL20671134 0.91 AHCY (0.51) AHCYLMNANT5EHIF1APNP
Islatravir SCHEMBL2528556 0.91 AHCY (0.51) AHCYLMNANT5EHIF1APNP
Islatravir SCHEMBL19815536 0.91 AHCY (0.51) AHCYLMNANT5EHIF1APNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1589026-B1 4'-C-Substituted-2-Haloadenosine derivative YAMASA CORP (JP) 2008-03-12 — — EP claimed
US-7339053-B2 4′-C-substituted-2-haloadenosine derivative YAMASA CORPORATION (JP) 2008-03-04 — — US claimed
EP-1589026-A1 4'-C-Substituted-2-Haloadenosine derivative YAMASA CORPORATION (JP) 2005-10-26 — — EP claimed
US-20050215512-A1 4' -C-substituted-2-haloadenosine derivative YAMASA CORPORATION (JP) 2005-09-29 — — US claimed
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. 2023-11-23 — — US disclosed
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. 2023-11-23 — — US disclosed
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. 2023-11-23 — — US disclosed
WO-2023178133-A9 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. (US) 2023-10-26 — — WO disclosed
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS INC (US) 2023-09-21 — — US disclosed
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS INC (US) 2023-09-21 — — US disclosed
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS INC (US) 2023-09-21 — — US disclosed
US-8039614-B2 4' -C-substituted-2-haloadenosine derivative YAMASA CORPORATION (JP) 2011-10-18 — — US disclosed
US-7625877-B2 4′-c-substituted-2-haloadenosine derivative YAMASA CORPORATION (JP) 2009-12-01 — — US disclosed
US-20090234110-A1 4' -C-substituted-2-haloadenosine derivative KOHGO SATORU 2009-09-17 — — US disclosed
US-20080153774-A1 Acquired Immune Deficiency Syndrome (AIDS); 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine; anti-HIV activity, particularly against a multi-drug-resistant HIV strain; less cytotoxicity, exhibit resistance to inactivation by adenosine deaminase KOHGO SATORU 2008-06-26 — — US disclosed
EP-1589026-B1 4'-C-Substituted-2-Haloadenosine derivative YAMASA CORP (JP) 2008-03-12 — — EP disclosed
US-7339053-B2 4′-C-substituted-2-haloadenosine derivative YAMASA CORPORATION (JP) 2008-03-04 — — US disclosed
EP-1589026-A1 4'-C-Substituted-2-Haloadenosine derivative YAMASA CORPORATION (JP) 2005-10-26 — — EP disclosed
US-20050215512-A1 4' -C-substituted-2-haloadenosine derivative YAMASA CORPORATION (JP) 2005-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 AHCY 3405/4885LMNA 2032/4885NT5E 865/4885
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 AHCY 3405/4885LMNA 2032/4885NT5E 865/4885
US-20080153774-A1 Acquired Immune Deficiency Syndrome (AIDS); 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine; anti-HIV activity, particularly against a multi-drug-resistant HIV strain; less cytotoxicity, exhibit resistance to inactivation by adenosine deaminase ADA, PNP, DCTD AHCY 69/4885LMNA 4513/4885NT5E 49/4885
US-20050215512-A1 4' -C-substituted-2-haloadenosine derivative ADORA1, ADORA2A, ADORA3 AHCY 259/4885LMNA 3258/4885NT5E 170/4885
US-20090234110-A1 4' -C-substituted-2-haloadenosine derivative ADORA1, ADORA2A, ADORA3 AHCY 59/4885LMNA 3655/4885NT5E 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.